Table 1.
Clinical features of 42 PTFL patients
| Case no. | Sex | Age, y | Anatomic site | Stage | Treatment | Follow-up, mo |
|---|---|---|---|---|---|---|
| PTFL1 | M | 16 | Midline cervical LN | NA | NA | NA |
| PTFL2 | M | 19 | Submental LN | I | Excision | 38 NED |
| PTFL3 | M | 12 | Left cervical LN | I | Excision | 31 NED |
| PTFL4 | M | 13 | Left cervical LN | NA | NA | NA |
| PTFL5 | M | 18 | Left cervical LN | NA | NA | NA |
| PTFL6 | M | 17 | Submandibular LN | NA | NA | NA |
| PTFL7 | M | 14 | Cervical LN | NA | NA | NA |
| PTFL8 | M | 27 | Right cervical LN | NA | NA | NA |
| PTFL9 | M | 19 | Cervical LN | NA | NA | NA |
| PTFL10 | M | 17 | Left cervical LN | NA | NA | NA |
| PTFL11 | M | 23 | Cervical LN | NA | NA | NA |
| PTFL12 | M | 5 | Right femoral LN | NA | NA | NA |
| PTFL13* | M | 12 | Posterior auricular LN | II | CHOP | 36 NED |
| PTFL14 | M | 12 | Left submandibular LN | NA | NA | NA |
| PTFL15* | M | 14 | Cervical LN | I | R, C, doxo | 8 NED |
| PTFL16* | M | 15 | Axillary LN | NA | R-CHOP | 96 NED |
| PTFL17* | M | 17 | Left cervical LN | I | CHOP | 30 NED |
| PTFL18* | M | 20 | Right thigh LN | I | R-CHOP, Rx | 78 NED |
| PTFL19* | M | 20 | Right jugular LN | I | Excision | 2 NED |
| PTFL20* | M | 21 | Occipital LN | I | R-CHOP | 18 NED |
| PTFL21 | M | 14 | Left intraparotid LN | I | Excision | 19 NED |
| PTFL22 | M | 15 | Cervical LN | I | Excision | 51 NED |
| PTFL23 | M | 5 | Right cervical LN | I | NA | 36 NED |
| PTFL24 | M | 6 | Upper extremity mass | I | Excision | 44 NED |
| PTFL25 | M | 21 | Right inguinal LN | NA | NA | NA |
| PTFL26 | F | 17 | Left cervical LN | II | Rx | 48 NED |
| PTFL27 | M | 17 | Right prehyoidal LN | I | Excision | 48 NED |
| PTFL28 | M | 10 | Right cervical LN | I | Excision | 24 NED |
| PTFL29 | M | 15 | Right maxillary sinus LN | I | Excision | 24 NED |
| PTFL30 | M | 23 | Inguinal LN | I | R, Rx | 7 NED |
| PTFL31 | M | 17 | Left cervical LN | I | R, Rx | 51 NED |
| PTFL32 | M | 17 | Cervical LN | NA | NA | NA |
| PTFL33 | M | 15 | Parotid gland LN | I | R-CHOP | 48 NED |
| PTFL34 | M | 11 | Post auricular LN | NA | NA | NA |
| PTFL35 | M | 8 | Left LN axillary | NA | NA | NA |
| PTFL36 | M | 14 | Submandibular LN | I | NA | NA |
| PTFL37 | M | 16 | Left parotid LN | I | Excision | 36 NED |
| PTFL38* | M | 17 | Submandibular LN | I | Excision | 71 NED |
| PTFL39 | F | 20 | Parotid gland LN | I | NA | NA |
| PTFL40 | M | 22 | Cervical LN | NA | NA | NA |
| PTFL41 | M | 20 | Parotid gland LN | I | Excision | 12 NED |
| PTFL42 | M | 31 | Cervical LN | I | NA | NA |
C, cyclophosphamide; CHOP, cyclophosphamide, adriamycin, vincristine, prednisone; doxo, doxorubicin; F, female; M, male; NA, not available; NED, not evidence of disease; R, rituximab; Rx, local radiation.
*
These cases were previously reported by Liu et al.5